Nasdaq:NGM

--NGM936, a ILT3 x CD3 bispecific T cell engager product candidate, potently induced T cell dependent cytotoxicity (TDCC) against ILT3+ AML cells while inducing minimal cytokine release in preclinical in vivo and in vitro studies--…

NGM707 was generally well tolerated to the highest dose evaluated (1800 mg) in the monotherapy escalation; maximum tolerated dose was not reachedLinear pharmacokinetics (PK) was observed at doses ≥200 mg, and analysis of peripheral…

--Poster presentation to showcase NGM Bio’s in vitro and in vivo research supporting development of NGM936, a ILT3 x CD3 bispecific T cell engager product candidate engineered to direct T cell-mediated killing of ILT3-positive cancer…